Navigation Links
Devicor Medical Products Actively Seeking First Acquisition
Date:3/10/2009

$250 million of committed equity capital immediately available to support growth strategy

PLEASANT PRAIRIE, Wis., March 10 /PRNewswire/ -- Tom Daulton, the former Cardinal Health executive recently tapped to head Devicor Medical Products, LLC, announced today that Devicor is actively seeking its first acquisition as it begins building a market-leading medical device company in the highly attractive healthcare industry.

"With our strong, available capital we are actively pursuing a strategic acquisition to serve as Devicor's platform," says Daulton.

Devicor was created in partnership with GTCR Golder Rauner, LLC (GTCR), one of the nation's leading private equity firms, which initially committed $250 million of equity capital to support Devicor's growth strategy. Daulton anticipates growing Devicor into an industry-leading medical device company through a combination of capital investment, ongoing R&D investment, organic growth, and acquisitions.

Devicor is currently looking to acquire established interventional medical device businesses that manufacture and sell products to clinicians in settings such as hospitals, surgery centers, or ambulatory clinics. Initial acquisitions are expected to provide infrastructure and personnel in key areas such as manufacturing, R&D, engineering, sales & marketing, finance, and human resources.

Daulton's career spans two decades in senior health care management roles at Baxter Healthcare, Allegiance Healthcare and Cardinal Health in both domestic and international positions. Most recently, Daulton served as General Manager of Cardinal's Interventional Specialties and Med Systems divisions, both fast-growing businesses, where he dramatically expanded revenue through a combination of organic growth, licensing and acquisitions.

"First and foremost, Devicor is a medical device company," says Daulton. "The financial side of our business is critically important, and we're enthusiastic about the number of compelling investment opportunities we see in the market. But, at the end of the day, we're looking to advance the medical device industry and improve patient outcomes by building on something that works."

About Devicor Medical Products, LLC

Devicor Medical Products, headquartered in Pleasant Prairie, Wisconsin, is a global medical device company focused on acquiring and developing clinical preference medical devices and companies. For more information, please visit www.devicormedical.com or call (262) 857-9300.

About GTCR

Founded in 1980, GTCR Golder Rauner, LLC is a leading private equity investment firm and long-term strategic partner for outstanding management teams. The Chicago-based firm pioneered the investment strategy of identifying and partnering with exceptional executives to acquire and build companies through a combination of acquisitions and strong internal growth. GTCR currently manages more than $8 billion of equity capital invested in a wide range of companies and industries. More information about GTCR can be found at www.gtcr.com.


'/>"/>
SOURCE Devicor Medical Products
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: